Abstract:
The B-cell CLL/lymphoma 11B gene (BCL11B) plays a crucial role in T-cell development, but its role in T-cell malignancies is still unclear. To study its role in the development of T-cell neoplasms, we generated an inducible BCL11B knockout in a murine T cell leukemia/lymphoma model. Mice, bearing human oncogenes TAL BHLH Transcription Factor 1 (TAL1; SCL) or LIM Domain Only 1 (LMO1), responsible for T-cell acute lymphoblastic leukemia (T-ALL) development, were crossed with BCL11B flox/flox and with Cre-ER/lox mice. The mice with a single oncogene BCL11B flox/flox/CRE<sup>tg</sup>/TAL1<sup>tg</sup> or BCL11B flox/flox/CRE<sup>tg</sup>/LMO1<sup>tg</sup> were healthy, bred normally, and were used to maintain the mice in culture. When crossed with each other, >90% of the double transgenic mice BCL11B flox/flox/CRE<sup>tg</sup>/TAL1<sup>tg</sup>LMO1<sup>tg</sup>, within 3 to 6 months after birth, spontaneously developed T-cell leukemia/lymphoma. Upon administration of synthetic estrogen (tamoxifen), which binds to the estrogen receptor and activates the Cre recombinase, the BCL11B gene was knocked out by excision of its fourth exon from the genome. The mouse model of inducible BCL11B knockout generated can be used to study the role of this gene in cancer development and the potential therapeutic effect of BCL11B inhibition in T-cell leukemia and lymphoma.

Keywords: BCL11B; TAL1; LMO1; CRE-ER/lox; T-ALL; TCL; mouse model

1. Introduction

T-cell neoplasms, including T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma (TCL), divided into peripheral T-cell lymphomas (PTCL) and cutaneous T-cell lymphomas (CTCL), comprise a heterogeneous group of hematopoietic tumors. T-ALL is an aggressive malignancy of early T-cell progenitors characterized by high numbers of blast cells in the bone marrow and peripheral blood, enlargement of mediastinal lymph nodes, and often central nervous system involvement. T-ALL has an incidence of 0.3/100,000
and accounts for approximately 15% of pediatric and 25% of adult ALL cases [1]. PTCL and CTCL originate from mature T-cells, have an incidence of 1.0/100,000 and 0.8/100,000 respectively, and together constitute 15% of all non-Hodgkin lymphomas (NHL) in the USA [1]. Due to the ageing of the population, the incidence of TCL is increasing. These neoplasms often present at an advanced stage at the time of diagnosis, and most commonly have an aggressive clinical course requiring prompt treatment. In contrast to B-cell precursor ALL, which has a very good prognosis with conventional therapy, and B-cell NHL, in which substantial clinical progress has been made with the introduction of monoclonal antibodies such as Rituximab, no comparable advances have been seen in T-ALL and PTCL.

Similar to other types of hematopoietic malignancies, T-cell neoplasms are caused by genetic alterations in hematopoietic precursors (T-ALL) or more mature T-cells (PTCL and CTCL), leading to a variety of changes, including loss of cell cycle control, unlimited self-renewal capacity, impaired differentiation, hyperproliferation and loss of sensitivity to death signals [2,3]. To improve the prognosis in T-cell malignancies, new, gene-targeted therapies have to be developed.

The B-cell CLL/lymphoma 11B gene (BCL11B) is a key player in T-cell development [4], but its role in T-cell malignancies is still unclear. Our group originally identified a chromosomal rearrangement in T-ALL involving BCL11B [5]. We found a high expression of BCL11B in T-ALL and showed that the in vitro suppression of the BCL11B gene leads to massive apoptosis in malignant, but not in normal T-cells [5,6]. Therefore, BCL11B might be an attractive target for the specific therapy of T cell leukemia and lymphomas.

TAL BHHL Transcription Factor 1 (TAL1;SCL) and LIM Domain Only 1 (LMO1) are oncogenes whose activation plays an important role in the development of a fraction of human T-ALL. TAL-1 is an essential transcription factor in normal and malignant hematopoiesis. It is required for the specification of the blood program during the development, adult hematopoietic stem cell survival and quiescence, and terminal maturation of select blood lineages [7]. Following ectopic expression, caused by a chromosomal translocation t(1;14) or a fusion to the STIL Centriolar Assembly Protein (STIL) exogenous promoter, TAL-1 contributes to oncogenesis in T-ALL. TAL1 activities are all mediated through the nucleation of a core quaternary protein complex (TCL1:E-protein:LMO1/2:LDB1) and the recruitment of additional regulators in a lineage- and stage-specific context. LMO1 belongs to a large family of proteins that are required for many developmental processes and are implicated in the onset or the progression of several cancers, including T cell leukemia, breast cancer and neuroblastoma. It contains two protein-interacting LIM domains that operate through nucleating the formation of new transcriptional complexes and/or by disrupting existing transcriptional complexes to modulate gene expression programs. Through these activities, LMO1 has important cellular roles in processes that are relevant to cancer such as self-renewal, cell cycle regulation and metastasis [8]. Transgenic mice bearing both TCL1 and LMO1 human oncogenes spontaneously develop T cell malignancies [9]. Here, we report the generation of a new model of inducible BCL11B knockout in TCL1/LMO1 transgenic mice to study the role of this gene in T cell malignancies.

2. Results

Four transgenic mouse strains: BCL11B<sup>flox/WT</sup>, Cre<sup>tg</sup>, SCL<sup>tg</sup> and LMO1<sup>tg</sup> were sequentially crossed in order to obtain a BCL11B<sup>flox/flox</sup>Cre<sup>tg/tg</sup>SCL<sup>tg</sup>LMO1<sup>tg</sup> mouse model of inducible BCL11B knockout in spontaneously developing T cell malignancies (Figure 1).

2.1. Establishment of BCL11B<sup>flox/flox</sup> LMO1<sup>tg</sup> and BCL11B<sup>flox/flox</sup> TAL1<sup>tg</sup> Mice

Heterozygous BCL11B<sup>flox/WT</sup> mice were crossed with either LMO1<sup>tg</sup> or TAL1<sup>tg</sup> transgenic mice (Figure 2A). Subsequently, BCL11B<sup>flox/WT</sup>LMO1<sup>tg</sup> and BCL11B<sup>flox/WT</sup>TAL1<sup>tg</sup> mice were crossed to generate homozygous BCL11B<sup>flox/flox</sup> mice with either the LMO1 or TAL1 oncogene: BCL11B<sup>flox/flox</sup>LMO1<sup>tg</sup> and BCL11B<sup>flox/flox</sup>TAL1<sup>tg</sup> (Figure 2B).
Figure 1. Scheme of transgenic mice crossing to generate inducible BCL11B knockout in spontaneously developing T cell malignancies.

Figure 2. Establishment of BCL11B\textsuperscript{flox/flox} LMO1\textsuperscript{tg} and BCL11B\textsuperscript{flox/flox} TAL1\textsuperscript{tg} mice. (A) Generation of heterozygous BCL11B\textsuperscript{flox/WT} LMO1\textsuperscript{tg} and BCL11B\textsuperscript{flox/WT} TAL1\textsuperscript{tg} mice. Genotypes of the parents (F: female; M: male) are indicated on the top, the identification numbers of the progeny below, the photo the genotypes of the progeny below, the size of the DNA ladder in bp on the left, and the location of multiplex PCR products on the right. The BCL11B\textsuperscript{flox/WT} LMO1\textsuperscript{tg} and BCL11B\textsuperscript{flox/WT} TAL1\textsuperscript{tg} mice used for further crossing are in bold. MW 1: Molecular weight marker 1—GeneRuler 50 bp (Thermo Scientific). (B) Generation of homozygous BCL11B\textsuperscript{flox/flox} LMO1\textsuperscript{tg} and BCL11B\textsuperscript{flox/flox} TAL1\textsuperscript{tg} mice. The homozygous BCL11B\textsuperscript{flox/flox} mouse with either LMO1\textsuperscript{tg} or TAL1\textsuperscript{tg} oncogenes are in bold. The homozygous BCL11B\textsuperscript{flox/flox} mouse with both oncogenes is in bold and is indicated by an asterisk (*). MW 2: Molecular weight marker 2—GeneRuler 1 kb (Thermo Scientific).

2.2. Introduction of the Cre/ESR1 Recombinase Construct to the BCL11B\textsuperscript{flox/flox} LMO1\textsuperscript{tg} and BCL11B\textsuperscript{flox/flox} TAL1\textsuperscript{tg} Mice

BCL11B\textsuperscript{flox/flox} LMO1\textsuperscript{tg} and BCL11B\textsuperscript{flox/flox} TAL1\textsuperscript{tg} mice were crossed with the heterozygous C57BL/6-Gt(Rosa)26Sor\textsuperscript{tm9(Cre/ESR1)Arte} (Cre\textsuperscript{tg}) mice. Subsequently, BCL11B\textsuperscript{flox/flox} LMO1\textsuperscript{tg}Cre\textsuperscript{tg} \textsuperscript{tg} and BCL11B\textsuperscript{flox/flox} TAL1\textsuperscript{tg}Cre\textsuperscript{tg} \textsuperscript{tg} were crossed with each other to obtain mice homozygous for the Cre construct: BCL11B\textsuperscript{flox/flox} LMO1\textsuperscript{tg}Cre\textsuperscript{tg} \textsuperscript{tg} and BCL11B\textsuperscript{flox/flox} TAL1\textsuperscript{tg}Cre\textsuperscript{tg} \textsuperscript{tg}. Those mice were healthy and reproduced normally.

2.3. Generation of the Final Experimental Mouse Model of Inducible BCL11B Knockout in T-Cell Malignancies

The BCL11B\textsuperscript{flox/flox} Cre\textsuperscript{tg} \textsuperscript{tg} TAL1\textsuperscript{tg} and BCL11B\textsuperscript{flox/flox} Cre\textsuperscript{tg} \textsuperscript{tg} LMO1\textsuperscript{tg} animals were mated, and one month old progeny were genotyped via PCR from tail DNA. One fourth of the progeny carried both oncogenes (BCL11B\textsuperscript{flox/flox} LMO1\textsuperscript{tg} TAL1\textsuperscript{tg} Cre\textsuperscript{tg} \textsuperscript{tg}), and >90% of them developed T-ALL and were used for studies. The animals carrying only one oncogene,
either LMO1 (BCL11Bflox/floxCREtg/tg/LMO1tg) or TAL1 (BCL11Bflox/floxCREtg/tg/TAL1tg), were healthy, bred normally and were used to maintain the mice in culture. Mice born without oncogenes (BCL11Bflox/floxCREtg/tg) were used as a control.

2.4. Creation of the BCL11Bflox/delCREtg/tgLMO1tg and BCL11Bflox/delCREtg/tgTAL1tg Mice

To increase the efficacy of the BCL11B knockout, a heterozygous mouse strain with an inherited deletion of the BCL11B gene (BCL11Bflox/del) was generated by inducing gene deletion in one of the parents by tamoxifen administration. Surprisingly, almost all (29 out of 30) offspring were born with one deleted allele (Figure 3). For further breeding, BCL11Bflox/del and BCL11Bflox/flox mice were coupled to avoid the bi-allelic deletion of BCL11B, which was previously described [10] and also proven by us to be lethal. Similarly to the previously described animals with an intact LMO1 locus, the animals with BCL11Bflox/delCREtg/tgLMO1tg mice were mated with the BCL11Bflox/floxCreLMO1tg/tg, or BCL11Bflox/floxCREtg/tgLMO1tg with BCL11Bflox/delCREtg/tgTAL1tg. One month old progeny were genotyped via PCR from tail DNA. One fourth of the progeny carried both oncogenes, and half of them carried the BCL11B deletion (BCL11Bflox/delLMO1tg/TAL1tg/Cretg/tg).

![Figure 3. Creation of the BCL11Bflox/delCREtg/tgLMO1tg/TAL1tg mice with germline hemizygous BCL11B knockout. Mice 643 and 645 are offspring of the tamoxifen-induced BCL11B knockout mother with LMO1tg and untreated father. Mice 646 and 647 are offspring of the tamoxifen-induced BCL11B knockout mother and untreated father, both without oncogenes. MW 1: Molecular weight marker 1—GeneRuler 50 bp (Thermo Scientific).](image)

2.5. Diagnosis of Hematologic Malignancies

As originally reported by Aplan et al., within 3–6 months after birth the progeny, carrying both oncogenes (LMO1 and TAL1), spontaneously developed an aggressive T cell leukemia/lymphoma [9]. Starting from the fourth month of life, every two weeks the LMO1/TAL1 mice were monitored for the development of malignancy. Lymphoma development was assessed by palpation and magnetic resonance imaging (MRI) (Figure 4), and the leukemia development was determined based on white blood cell (WBC) counting and peripheral blood smear analysis (Figure 5). Leukemia was diagnosed when the WBC was >10,000 cell/µL and/or the blast content >20%.
2.6. Determination of the Immunophenotype of the Malignant Disease by Flow Cytometry

The diagnosis of T cell malignancy was further confirmed by FC of the peripheral blood. In contrast to healthy mice, in animals that developed T cell malignancies, besides an increased ratio of CD3+ cells, double-positive CD4+/CD8+, CD25+ or terminal deoxynucleotidyl transferase (TdT+) subsets of T cells were detected (Figure 6). The most common feature of all cases was the increased (30–90%) subset of CD3+ leukocytes (17/23; 74%). In 61% of the cases (14/23), double-positive CD4+/CD8+ T cells were observed, normally not present in the peripheral blood. In the majority of the CD4+/CD8+ cases, abnormal TdT+ (10/14; 71%) and CD25+ (8/14; 57%) cell subsets were also observed. In 10/13 (77%) of the analyzed cases, NK cell-specific antigen NK-1.1 was expressed, in half of the cases as a sole abnormal phenotype, in the other half accompanied by the CD4/CD8 phenotype, of which three also expressed TdT.
LMO1 with each other, 90% of the double transgenic animals, BCL11B physiological role of BCL11B (model, the animals carrying only one oncogene, in therapeutic approaches, animal models of disease are needed. BCL11B regulation resulting in apoptosis of malignant T cells. To better understand the role of others, including our studies, suggested suppressor and that inactivating mutations played a role in tumor development [13,14], alterations are contradictory. While some studies postulated that CD25+/CD44-, and TdT+ cells. (CD25+/CD44+ and NK-1.1 cells.

Reduced an inherited knockout of one of the alleles. The animals were born with one floxed system, using synthetic estrogen (tamoxifen) administration. BCL11B gene can be inactivated at any time by induction of the Cre-lox knockout system, using synthetic estrogen (tamoxifen) administration.

Figure 6. Determination of malignant T cell immunophenotype by flow cytometry analysis. (A) Mouse 795 without signs of malignancy, (B) Mouse 742 with increased ratio of CD3+, CD4+/CD8+, CD25+/CD44-, and TdT+ cells. (C) Mouse 781 with increased ratio of CD3+, CD4+/CD8+, CD25+/CD44+ and NK-1.1 cells.

3. Discussion

During the last two decades, extensive knowledge has been accumulated about the physiological role of BCL11B and the role of its mutations in inherited diseases. Although there are several reports on the involvement of BCL11B in hematological malignancies, including gene rearrangements, mutations and overexpression, the role of BCL11B in the development of the disease has not yet been conclusively clarified [11,12]. Additionally, the hypotheses on the possible mechanism of malignant transformation caused by BCL11B alterations are contradictory. While some studies postulated that BCL11B acted as a tumor suppressor and that inactivating mutations played a role in tumor development [13,14], others, including our studies, suggested BCL11B as being an oncogene [6,15] and its downregulation resulting in apoptosis of malignant T cells. To better understand the role of BCL11B in the pathogenesis of T cell malignancies and to test the efficacy of new therapeutic approaches, animal models of disease are needed.

In this study, we report the generation of a new model of inducible BCL11B knockout in LMO1/TAL1 transgenic mice spontaneously developing T cell malignancies. In this model, the animals carrying only one oncogene, LMO1\(^{tg}\) or TAL1\(^{tg}\), are healthy and immunocompetent. They are easy to maintain in culture and breed normally. When crossed with each other, 90% of the double transgenic animals, LMO1\(^{tg}\)/TAL1\(^{tg}\), within 3–6 months from birth, spontaneously develop T cell leukemia/lymphoma, resembling human T cell malignancies [9]. Since the animals possess the BCL11B\(^{flox/flox}\) CRE\(^{tg/tg}\) genetic modification, the BCL11B gene can be inactivated at any time by induction of the Cre-lox knockout system, using synthetic estrogen (tamoxifen) administration.

To improve the efficacy of the BCL11B knockout, we modified that system and introduced an inherited knockout of one of the alleles. The animals were born with one floxed
and one knocked-out BCL11B allele (BCL11B<sup>flox/del</sup>CRE<sup>tg/tg</sup>LMO1<sup>tg</sup> and BCL11B<sup>flox/del</sup>CRE<sup>tg/tg</sup>T AL1<sup>tg</sup>), were healthy, bred normally, and passed the knocked-out allele to half of their offspring. As originally reported by Wakabayashi et al. [10], the germine knockout of both BCL11B alleles was lethal, and the animals died shortly after birth.

Besides the direct pro-apoptotic effect on malignant T cells, BCL11B suppression was shown to cause the transformation of normal T cells into induced T-to-natural killer (ITNK) cells [16]. Since ITNK cells killed tumor cells in vitro and in vivo, the inhibition of BCL11B may additionally exert its anti-tumor activity by inducing normal T cells to kill the remaining malignant T cells. In our previous studies, we showed that an increased expression of BCL11B leads to chemoresistance accompanied by G1 accumulation [17]. It can be speculated that the opposite, the suppression of BCL11B, should lead to an increased chemotherapy susceptibility. This suggests that combining BCL11B inhibition with chemotherapy could increase the efficacy of targeting cancer cells.

4. Materials and Methods

4.1. Mouse Models

Heterozygous transgenic mice bearing constructs which express TAL BHLH Transcription Factor 1 (TAL1;SCL) mRNA driven by a fusion to the STIL Centriolar Assembly Protein (STIL) exogenous promoter and LIM Domain Only 1 (LMO1), mimicking common gene dysregulations associated with human T-ALL, were kindly provided by Peter Aplan (National Institute of Health/National Cancer Institute, Bethesda, MD, USA). These mice, bearing human oncogenes, TAL1 or LMO1, responsible for T-cell acute lymphoblastic leukemia (T-ALL) development, are healthy and breed normally. When crossed with each other, the double transgenic mice TAL1<sup>tg/tg</sup>/LMO1<sup>tg/tg</sup>, within 3 to 6 months from birth, spontaneously develop T-cell leukemia/lymphoma [9].

The heterozygous BCL11B floxed mice were kindly provided by Philippe Kastner (Institut de Génétique et de Biologie Moléculaire et Cellulaire, Université de Strasbourg, France) with the permission of Mark Leid (Department of Integrative Biosciences, Oregon Health & Science University, Portland, OR, USA) [18].

The C57BL/6-Gt(ROSA)26Sor<sup>tm9(Cre/ESR1)Arte</sup> (Cre<sup>tg</sup>) mice, with inducible Cre recombinase, were purchased from Artemis (Koeln, Germany) [19]. Upon administration, synthetic estrogen (tamoxifen) binds to the estrogen receptor and activates the Cre recombinase. All studies involving animals were performed with the approval of the Local Ethical Committee for Animal Experiments in Poznan (approval code LKE 2/2018).

4.2. Genotyping

Genetic modifications were determined via PCR from tail DNA in one month old mice. For the determination of the presence of LoxP sequences within the BCL11B gene, the 5′ BCL6912f (mm39; chr12:107,883,573-592) TCGGAAGCCATGTGTGTTCT and the 3′ BCL7202r (mm39; chr12:107,883,863-844) TAGATCCCGTGTTCCCTTGC primers were used, amplifying a 291 bp fragment of the intron/fourth exon border of BCL11B in the wild type animals. In the BCL11B floxed mice, with the inserted LoxP sequence and fragments of the cloning vector, the amplicon was 342 bp long.

For the presence of Rosa 26 Cre locus 1242_1: CCATCATCGAAGCTTCACTGAAG and 1242_2: GGAGTTTCAATACCCGAGATCATGC primers were used, amplifying a 315 bp fragment; and as a reaction control 1260_1: GAGACTCTGGCTACTCATCC and 1260_2: CCTTCAGCAAGAGCTGGGGAC primers were used, amplifying a 585 bp fragment of CD79b, as recommended by the supplier (Artemis).

For the detection of the STIL-TAL1 fusion product SILf: (hg38; chr1:47,314,077-058) GCTCCC-TACCTCGACAAACGA and SCLR: (hg38; chr1:47,220,065-084) ATGTGTGGAGATCCAGTCC primers were used, amplifying a 250 bp DNA fragment [9]. For the detection of LMO1, LMO1f: (chr11:8,230,382-363) AAGTTGTCGGTGCTGTACTG and LMO1r: (mm39; chr11:8,226,996-7,015) GCGAAGGACGTGAGTGATA primers were used, amplifying a 197 bp fragment of the spliced exons 2 and 3 [20].
4.3. Magnetic Resonance Imaging (MRI)

MRI experiments were carried out using a preclinical horizontal scanner operating at 9.4 T (Agilent) equipped with a 600 mT/m gradient system, and a 40-mm i.d. quadrature millipede type coil was used. During the imaging experiment, animals were anesthetized with 2% isoflurane in a 20/80 air-oxygen mixture (induction 4% isoflurane) and put in a specially designed holder. The temperature of the animal was kept at 37 °C, and the respiration of the animal was also monitored and used to synchronize MRI experiments (1030, SA Instruments Inc., Stony Brook, NY, USA).

MRI images of the proton spin density were collected at two localizations of each animal (abdomen area and neck area) using a fast spin-echo sequence (FSEMS) with the following parameters: TR = 5 s, effective TE = 10 ms, ETL = 8, FOV 35 × 35 mm, 2 averages, matrix size 256 × 256, slices from 12 to 30 depending on animal and localization (slice thickness 1 mm).

4.4. Induction of BCL11B Knockout by Tamoxifen Administration

Tamoxifen (Sigma-Aldrich, Burlington, MA, USA) was dissolved in corn oil at a concentration of 10 mg/mL by shaking overnight at 37 °C. To induce Cre recombinase synthesis followed by knockout of the floxed BCL11B gene, the mice were injected intraperitoneally with 1 mg of tamoxifen (100 µL of oil solution) for 3 subsequent days. The efficacy of deletion was checked 7 days after the third administration.

4.5. Detection of CreER-Mediated BCL11B Knockout

For the detection of the Cre-mediated deletion of the fourth exon of BCL11B, competitive PCR was performed with the BCL6912f, BCL7202r and BCL4812f (mm39; chr12:107,881,068-087) AATCCCAATGCACACTTTTC primers, amplifying, besides the floxed BCL11B locus (342 bp), the knocked-out locus (451 bp).

4.6. Flow Cytometry

Flow cytometry analysis (FC) was performed on an Amnis® FlowSight® Flow Cytometer (Luminex; Austin, TX, USA) and CytoFLEX S Flow Cytometer (Beckman Coulter; Indianapolis, IN, USA). The following antibodies (BD Pharmigen, San Diego, CA, USA) were used for surface markers: Pacific Blue™ Hamster Anti-Mouse CD3e (558214), FITC Rat Anti-Mouse CD3 Molecular Complex (561798), PE Rat Anti-Mouse CD4 (553048), APC Rat Anti-Mouse CD8a (553035), APC Rat Anti-Mouse CD25 (557192), PE Rat Anti-Mouse CD44 (553134), PE Rat Anti-Mouse CD335 (NKp46) (560757), APC Mouse Anti-Mouse NK.1.1 (CD161) (550627). For the intracellular staining terminal-deoxynucleotidyl transferase (TdT): TdT Monoclonal Antibody (19-3), APC, eBioscience™ (17-5846-82) was used. Peripheral blood samples were treated with Erythrocyte Lysis Buffer (Qiagen, Germantown, MD, USA), and leukocytes were directly used for surface marker staining, while for intracellular staining, cells were fixed and permeabilized using BD Cytosar/Cytoperm Kit (554714) and BD Cytoperm™ Permeabilization Buffer Plus (561651). The cut-off for positivity was set at 10% for CD4/CD8, CD25 and TdT, and at 20% for NK1.1. antibodies.

5. Conclusions

The mouse model we created can be used to study the function of BCL11B in T cell malignancies, especially the effect of BCL11B suppression. Since, to date, no specific BCL11B inhibitor has been invented, this model can be used as a proof of principle for the rationale of therapeutic BCL11B suppression in T cell neoplasms.
Author Contributions: Conceptualization, G.K.P.; methodology, D.K., K.I., T.Z., M.T., M.M., J.v.d.B. and G.D.; validation, G.K.P., D.K. and G.D.; investigation, D.K., K.I., K.N., T.Z., M.T., M.M., M.F. and M.B.; resources, G.K.P., J.v.d.B. and Y.L.; writing—original draft preparation, G.K.P., D.K. and K.I.; writing—review and editing, T.Z., D.J.-L., P.G., C.A.S., C.Z. and Y.L.; visualization, D.K., K.I. and K.N.; supervision, G.K.P., D.J.-L. and G.D.; project administration, G.K.P. and Y.L.; funding acquisition, G.K.P. and Y.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the National Science Center, Poland; Decision no. DEC-2013/09/B/NZ1/01867 (G.K.P., K.N., M.M., D.J.-L., M.F., M.B. and G.D.), the National Centre for Research and Development, Poland; Grant No. WPC/BCL/2019 (D.K., K.I., K.N., T.Z., M.T. and G.K.P.) and the Intergovernmental International Cooperation on Scientific and Technological Innovation project of the Ministry of Science and Technology, China: 2017YFE0131600 (C.Z. and Y.L.).

Institutional Review Board Statement: All studies involving animals were performed with the approval of the Local Ethical Committee for Animal Experiments in Poznan (approval code LKE 2/2018).

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: We thank Peter Aplan (National Institute of Health/National Cancer Institute, Bethesda, MD, USA) for kindly providing us with the LMO1 and SCL transgenic mice, Philippe Kastner (Institut de Génétique et de Biologie Moléculaire et Cellulaire, Université de Strasbourg, France) and Mark Leid (College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA) for kindly providing the BCL11B floxed mice. We express our gratitude to Anna Piliszek and Katarzyna Filimonow from the Department of Experimental Embryology Institute of Genetics and Animal Breeding, Polish Academy of Sciences, Jastrzebiec for resolving our initial breeding problems by embryo transfer.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Teras, L.R.; DeSantis, C.E.; Cerhan, J.R.; Morton, L.M.; Jemal, A.; Flowers, C.R. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J. Clin. 2016, 66, 443–459. [CrossRef] [PubMed]
2. Cortes, J.R.; Palomero, T. Biology and Molecular Pathogenesis of Mature T-Cell Lymphomas. Cold Spring Harb. Perspect. Med. 2021, 11, a035402. [CrossRef] [PubMed]
3. Shiraz, P.; Jehangir, W.; Agrawal, V. T-Cell Acute Lymphoblastic Leukemia—Current Concepts in Molecular Biology and Management. Biomedicines 2021, 9, 1621. [CrossRef] [PubMed]
4. Avram, D.; Califano, D. The multifaceted roles of Bcl11b in thymic and peripheral T cells: Impact on immune diseases. J. Immunol. 2014, 193, 2059–2065. [CrossRef] [PubMed]
5. Przybylski, G.K.; Dik, W.A.; Wancek, J.; Grabarczyk, P.; Majunke, S.; Martin-Subero, J.I.; Siebert, R.; Dölken, G.; Ludwig, W.-D.; Verhaaf, B.; et al. Disruption of the BCL11B gene through inv(14)(q11.2q32.31) results in the expression of BCL11B-TRDC fusion transcripts and is associated with the absence of wild-type BCL11B transcripts in T-ALL. Leukemia 2005, 19, 201–208. [CrossRef] [PubMed]
6. Grabarczyk, P.; Przybylski, G.K.; Depke, M.; Völker, U.; Bahr, J.; Assmus, K.; Bröker, B.M.; Walther, R.A.; Schmidt, C. Inhibition of BCL11B expression leads to apoptosis of malignant but not normal mature T cells. Oncogene 2007, 26, 3797–3810. [CrossRef] [PubMed]
7. Porcher, C.; Chagraoui, H.; Kristiansen, M.S. SCL/TAL1: A multifaceted regulator from blood development to disease. Blood 2017, 129, 2051–2060. [CrossRef] [PubMed]
8. Matthews, J.M.; Lester, K.; Joseph, S.; Curtis, D.J. LIM-domain-only proteins in cancer. Nat. Rev. Cancer 2013, 13, 111–122. [CrossRef] [PubMed]
9. Aplan, P.D.; Jones, C.A.; Chervinsky, D.S.; Zhao, X.; Ellsworth, M.; Wu, C.; McGuire, E.A.; Gross, K.W. An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice. EMBO J. 1997, 16, 2408–2419. [CrossRef] [PubMed]
10. Wakabayashi, Y.; Watanabe, H.; Inoue, J.; Takeda, N.; Sakata, J.; Mishima, Y.; Hitomi, J.; Yamamoto, T.; Utsuyama, M.; Niwa, O.; et al. Bcl11b is required for differentiation and survival of alphabeta T lymphocytes. Nat. Immunol. 2003, 4, 533–539. [CrossRef] [PubMed]
11. Bardelli, V.; Armani, S.; Pierini, V.; Di Giacomo, D.; Pierini, T.; Gorello, P.; Mecucci, C.; La Starza, R. T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness. Genes 2021, 12, 1118. [CrossRef] [PubMed]
12. Huang, X.; Du, X.; Li, Y. The role of BCL11B in hematological malignancy. Exp. Hematol. Oncol. 2012, 1, 22. [CrossRef] [PubMed]
13. Kominami, R. Role of the transcription factor Bcl11b in development and lymphomagenesis. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2012, 88, 72–87. [CrossRef] [PubMed]
14. Yoshikai, Y.; Sato, T.; Morita, S.; Kohara, Y.; Takagi, R.; Mishima, Y.; Kominami, R. Effect of Bcl11b genotypes and gamma-radiation on the development of mouse thymic lymphomas. *Biochem. Biophys. Res. Commun.* 2008, 373, 282–285. [CrossRef] [PubMed]
15. Huang, X.; Chen, S.; Shen, Q.; Chen, S.; Yang, L.; Grabarczyk, P.; Przybylski, G.K.; Schmidt, C.A.; Li, Y. Down regulation of BCL11B expression inhibits proliferation and induces apoptosis in malignant T cells by BCL11B-935-siRNA. *Hematology* 2011, 16, 236–242. [CrossRef] [PubMed]
16. Li, P.; Burke, S.; Wang, J.; Chen, X.; Ortiz, M.; Lee, S.C.; Lu, D.; Campos, L.; Goulding, D.; Ng, B.L.; et al. Reprogramming of T cells to natural killer-like cells upon Bcl11b deletion. *Science* 2010, 329, 85–89. [CrossRef] [PubMed]
17. Grabarczyk, P.; Nähse, V.; Delin, M.; Przybylski, G.; Depke, M.; Hildebrandt, P.; Völker, U.; Schmidt, C.A. Increased expression of bcl11b leads to chemoresistance accompanied by G1 accumulation. *PLoS ONE* 2010, 5, e12532. [CrossRef] [PubMed]
18. Golonzhka, O.; Liang, X.; Messaddeq, N.; Bornert, J.-M.; Campbell, A.L.; Metzger, D.; Chambon, P.; Ganguli-Indra, G.; Leid, M.; Indra, A.K. Dual role of COUP-TF-interacting protein 2 in epidermal homeostasis and permeability barrier formation. *J. Investig. Dermatol.* 2009, 129, 1459–1470. [CrossRef] [PubMed]
19. Seibler, J.; Zevnik, B.; Kuter-Luks, B.; Andreas, S.; Kern, H.; Hennek, T.; Rode, A.; Heimann, C.; Faust, N.; Kauselmann, G.; et al. Rapid generation of inducible mouse mutants. *Nucleic Acids Res.* 2003, 31, e12. [CrossRef] [PubMed]
20. Lin, Y.W.; DeVeney, R.; Barbara, M.; Iscove, N.N.; Nimer, S.D.; Slape, C.; Aplan, P.D. OLIG2 (BHLHB1), a bHLH transcription factor, contributes to leukemogenesis in concert with LMO1. *Cancer Res.* 2005, 65, 7151–7158. [CrossRef] [PubMed]